Other studies found that cancer cells were FOXP3 positive in 57% of HER2+ breast tumors [30] and in 66% of archival samples from human breast cancer patients [10], indicating that our sample of TNBC demonstrated a high expression of this protein and that FOXP3 may have different expression levels in subtypes of breast cancer, with specific prognostic implications. Here, ERBB2 is linked to breast carcinoma.